Tetraphase Pharmaceuticals, Inc.
(NASDAQ : TTPH)

( )
TTPH After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
JAZZJazz Pharmaceuticals Plc
0.49%125.932.2%$75.69m
ICPTIntercept Pharmaceuticals, Inc.
-0.34%110.8218.6%$71.32m
PRGOPerrigo Co. Plc
0.76%48.976.8%$64.65m
CTLTCatalent Inc
1.06%42.022.4%$44.70m
PTLAPortola Pharmaceuticals, Inc.
3.86%30.967.7%$44.48m
ICLRICON Plc
0.67%145.054.1%$35.20m
UTHRUnited Therapeutics Corporation
0.92%119.6314.4%$32.23m
HZNPHorizon Pharma plc
1.05%23.177.4%$31.02m
MDCOMedicines Company
3.17%24.7721.8%$29.68m
AERIAerie Pharmaceuticals, Inc.
1.66%41.756.9%$28.89m
ENDPEndo International Plc
0.48%10.578.9%$22.99m
PCRXPacira Pharmaceuticals, Inc.
2.52%40.6810.6%$22.24m
MDWDMediWound Ltd.
0.21%4.720.6%$4.99m
TBPHTheravance Biopharma Inc
2.30%27.569.9%$4.43m
SGYPSynergy Pharmaceuticals, Inc.
9.65%0.3126.3%$3.06m

Company Profile

Tetraphase Pharmaceuticals, Inc. engages in the development and production of novel antibiotics for serious and life-threatening bacterial infections. It is currently developing a product candidate, eravacycline, a fully synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Watertown, MA.